{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:45:33Z","timestamp":1761597933198},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T00:00:00Z","timestamp":1524009600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s10067-018-4084-4","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T01:20:56Z","timestamp":1524014456000},"page":"1625-1632","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Analysis of relapse rates and risk factors of tapering or stopping pharmacologic therapies in axial spondyloarthritis patients with sustained remission"],"prefix":"10.1007","volume":"37","author":[{"given":"Xiaochan","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,18]]},"reference":[{"issue":"5","key":"4084_CR1","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.berh.2014.10.005","volume":"28","author":"D Poddubnyy","year":"2014","unstructured":"Poddubnyy D, Gensler LS (2014) Spontaneous, drug-induced, and drug-free remission in peripheral and axial spondyloarthritis. Best Pract Res Clin Rheumatol 28(5):807\u2013818. \n                    https:\/\/doi.org\/10.1016\/j.berh.2014.10.005","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"6","key":"4084_CR2","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s10067-005-0132-y","volume":"25","author":"J Zochling","year":"2006","unstructured":"Zochling J, Bohl-Buhler MH, Baraliakos X, Feldtkeller E, Braun J (2006) Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis\u2014a population-based survey. Clin Rheumatol 25(6):794\u2013800. \n                    https:\/\/doi.org\/10.1007\/s10067-005-0132-y","journal-title":"Clin Rheumatol"},{"issue":"10","key":"4084_CR3","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1136\/annrheumdis-2011-201252","volume":"71","author":"D Poddubnyy","year":"2012","unstructured":"Poddubnyy D, Rudwaleit M, Haibel H, Listing J, Marker-Hermann E, Zeidler H, Braun J, Sieper J (2012) Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 71(10):1616\u20131622. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2011-201252","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"4084_CR4","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","volume":"75","author":"J Sieper","year":"2016","unstructured":"Sieper J, Listing J, Poddubnyy D, Song IH, Hermann KG, Callhoff J, Syrbe U, Braun J, Rudwaleit M (2016) Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis 75(8):1438\u20131443. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2015-207897","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"4084_CR5","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1093\/rheumatology\/kew033","volume":"55","author":"V Navarro-Compan","year":"2016","unstructured":"Navarro-Compan V, Plasencia-Rodriguez C, de Miguel E, Balsa A, Martin-Mola E, Seoane-Mato D, Canete JD (2016) Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review. Rheumatology 55(7):1188\u20131194. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kew033","journal-title":"Rheumatology"},{"issue":"2","key":"4084_CR6","first-page":"174","volume":"33","author":"S Arends","year":"2015","unstructured":"Arends S, van der Veer E, Kamps FB, Houtman PM, Bos R, Bootsma H, Brouwer E, Spoorenberg A (2015) Patient-tailored dose reduction of TNF-alpha blocking agents in ankylosing spondylitis patients with stable low disease activity in daily clinical practice. Clin Exp Rheumatol 33(2):174\u2013180","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"4084_CR7","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/annrheumdis-2014-205202","volume":"75","author":"J Zavada","year":"2016","unstructured":"Zavada J, Uher M, Sisol K, Forejtova S, Jarosova K, Mann H, Vencovsky J, Pavelka K (2016) A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. Ann Rheum Dis 75(1):96\u2013102. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2014-205202","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4084_CR8","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D Heijde van der","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landewe R, Baraliakos X, Van den Bosch F, Sepriano A, Regel A, Ciurea A, Dagfinrud H, Dougados M, van Gaalen F, Geher P, van der Horst-Bruinsma I, Inman RD, Jongkees M, Kiltz U, Kvien TK, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compan V, Ozgocmen S, Pimentel-Santos FM, Reveille J, Rudwaleit M, Sieper J, Sampaio-Barros P, Wiek D, Braun J (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76(6):978\u2013991. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2016-210770","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4084_CR9","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1111\/j.1756-185X.2012.01817.x","volume":"15","author":"M Can","year":"2012","unstructured":"Can M, Aydin SZ, Nigdelioglu A, Atagunduz P, Direskeneli H (2012) Conventional DMARD therapy (methotrexate-sulphasalazine) may decrease the requirement of biologics in routine practice of ankylosing spondylitis patients: a real-life experience. Int J Rheum Dis 15(6):526\u2013530. \n                    https:\/\/doi.org\/10.1111\/j.1756-185X.2012.01817.x","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"4084_CR10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/1756-185X.12986","volume":"20","author":"HW Tam","year":"2017","unstructured":"Tam HW, Yeo KJ, Leong PY, Chen CH, Li YC, Ma CM, Wang YH, Chiou JY, Wei JC (2017) Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: a nationwide population-based retrospective cohort study. Int J Rheum Dis 20(3):363\u2013370. \n                    https:\/\/doi.org\/10.1111\/1756-185X.12986","journal-title":"Int J Rheum Dis"},{"key":"4084_CR11","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/1756-185X.13124","volume":"21","author":"S Khanna Sharma","year":"2017","unstructured":"Khanna Sharma S, Kadiyala V, Naidu G, Dhir V (2017) A randomized controlled trial to study the efficacy of sulfasalazine for axial disease in ankylosing spondylitis. Int J Rheum Dis 21:308\u2013314. \n                    https:\/\/doi.org\/10.1111\/1756-185X.13124","journal-title":"Int J Rheum Dis"},{"issue":"6","key":"4084_CR12","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1136\/annrheumdis-2015-208593","volume":"75","author":"L Gossec","year":"2016","unstructured":"Gossec L, Portier A, Landewe R, Etcheto A, Navarro-Compan V, Kroon F, van der Heijde D, Dougados M (2016) Preliminary definitions of \u2018flare\u2019 in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative. Ann Rheum Dis 75(6):991\u2013996. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2015-208593","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4084_CR13","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s00296-014-3168-y","volume":"35","author":"E Kilic","year":"2015","unstructured":"Kilic E, Kilic G, Akgul O, Ozgocmen S (2015) Discriminant validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis: a cohort study. Rheumatol Int 35(6):981\u2013989. \n                    https:\/\/doi.org\/10.1007\/s00296-014-3168-y","journal-title":"Rheumatol Int"},{"issue":"1","key":"4084_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/ard.2010.138594","volume":"70","author":"P Machado","year":"2011","unstructured":"Machado P, Landewe R, Lie E, Kvien TK, Braun J, Baker D, van der Heijde D, Assessment of SpondyloArthritis international S (2011) Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 70(1):47\u201353. \n                    https:\/\/doi.org\/10.1136\/ard.2010.138594","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4084_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Braun J, Dougados M, Emery P, Fitzgerald O, Helliwell P, Kavanaugh A, Kvien TK, Landewe R, Luger T, Mease P, Olivieri I, Reveille J, Ritchlin C, Rudwaleit M, Schoels M, Sieper J, Wit M, Baraliakos X, Betteridge N, Burgos-Vargas R, Collantes-Estevez E, Deodhar A, Elewaut D, Gossec L, Jongkees M, Maccarone M, Redlich K, van den Bosch F, Wei JC, Winthrop K, van der Heijde D (2014) Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 73(1):6\u201316. \n                    https:\/\/doi.org\/10.1136\/annrheumdis-2013-203419","journal-title":"Ann Rheum Dis"},{"issue":"4 Suppl 78","key":"4084_CR16","first-page":"S47","volume":"31","author":"U Kiltz","year":"2013","unstructured":"Kiltz U, Baraliakos X, Braun J, van der Heijde D (2013) Withdrawal of medical therapies in axial spondyloarthritis: what would be the optimal trial design? Clin Exp Rheumatol 31(4 Suppl 78):S47\u2013S50","journal-title":"Clin Exp Rheumatol"},{"key":"4084_CR17","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1093\/rheumatology\/kew464","volume":"56","author":"CJ Edwards","year":"2017","unstructured":"Edwards CJ, Fautrel B, Schulze-Koops H, Huizinga TW, Kruger K (2017) Dosing down with biologic therapies: a systematic review and clinicians\u2019 perspective. Rheumatology 56:1847\u20131856. \n                    https:\/\/doi.org\/10.1093\/rheumatology\/kew464","journal-title":"Rheumatology"},{"issue":"9","key":"4084_CR18","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1007\/s00296-015-3288-z","volume":"35","author":"M Almirall","year":"2015","unstructured":"Almirall M, Salman-Monte TC, Lisbona MP, Maymo J (2015) Dose reduction of biological treatment in patients with axial spondyloarthritis in clinical remission: are there any differences between patients who relapsed and to those who remained in low disease activity? Rheumatol Int 35(9):1565\u20131568. \n                    https:\/\/doi.org\/10.1007\/s00296-015-3288-z","journal-title":"Rheumatol Int"},{"issue":"8","key":"4084_CR19","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.3899\/jrheum.160363","volume":"43","author":"E Lubrano","year":"2016","unstructured":"Lubrano E, Massimo Perrotta F, Manara M, D\u2019Angelo S, Addimanda O, Ramonda R, Punzi L, Olivieri I, Salvarani C, Marchesoni A (2016) Predictors of loss of remission and disease flares in patients with axial spondyloarthritis receiving antitumor necrosis factor treatment: a retrospective study. J Rheumatol 43(8):1541\u20131546. \n                    https:\/\/doi.org\/10.3899\/jrheum.160363","journal-title":"J Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-4084-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4084-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-4084-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T23:19:35Z","timestamp":1555543175000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-4084-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,18]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["4084"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-4084-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,18]]},"assertion":[{"value":"15 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study had been approved by the local ethics committee and was performed in accordance with the Declaration of Helsinki. All patients gave their informed consent prior to their inclusion in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}